Condition (MeSH)
Red-Cell Aplasia, Pure
ClinicalTrials.gov lists 75 trials for Red-Cell Aplasia, Pure or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
27 of the 75 trials are tagged with Red-Cell Aplasia, Pure itself; the rest are tagged with a narrower condition beneath it.
When did Red-Cell Aplasia, Pure trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 5 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 5 |
Showing 10 of 28 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Red-Cell Aplasia, Pure trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 12 |
| Phase 2 | 22 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 6 |
| Not applicable | 8 |
| Observational | 17 |
How many Red-Cell Aplasia, Pure trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 13 |
| Active, not recruiting | 1 |
| Completed | 40 |
| Terminated | 12 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Red-Cell Aplasia, Pure trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 6 |
| National Heart, Lung, and Blood Institute (NHLBI) | 6 |
| Novartis Pharmaceuticals | 5 |
| Bellicum Pharmaceuticals | 3 |
Which drugs are being tested for Red-Cell Aplasia, Pure? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Busulfan | 6 |
| Cytoxan | 5 |
| Melphalan | 4 |
| METHYLPREDNISOLONE | 4 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 10 |
| Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] | 8 |
| Cyclosporine 0.05% | 6 |
| IR Tacrolimus | 6 |
| Peripheral blood stem cell transplantation | 6 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Red-Cell Aplasia, Pure trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 28 | 5 |
| Sickle cell anaemia with crisis | 27 | 1 |
| Infection | 15 | 4 |
| Acute graft versus host disease | 12 | 2 |
| Sepsis | 11 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Red-Cell Aplasia, Pure? (31)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Molecular landscape of CD8<sup>+</sup> T cells in pure red cell aplasia. | Annals of hematology | 2025 | Yes |
| Patients with acquired pure red cell aplasia respond to PI3Kδ inhibitor rapidly. | American journal of hematology | 2024 | Yes |
| Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. | Blood cells, molecules & diseases | 2021 | Yes |
| Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone. | Blood cells, molecules & diseases | 2021 | Yes |
| Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency. | Annals of hematology | 2020 | Yes |
Showing 5 of 31 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.